The findings of a nested case-control study of the National Prostate Cancer Register of Sweden reveal no significant differences in prostate cancer risk among men who previously received testosterone replacement therapy (TRT) compared with that of the general population. However, further analyses revealed an increased risk of early (<1 year of TRT) favourable-risk prostate cancer and a decreased risk of aggressive prostate cancer >1 year after TRT. The investigators attribute this increase in early, favourable-risk disease to detection bias, while emphasizing that the decreased risk of aggressive disease warrants further investigation.
References
Loeb, S. et al. Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2016.69.5304 (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. Testosterone replacement affects disease risk. Nat Rev Urol 14, 327 (2017). https://doi.org/10.1038/nrurol.2017.48
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.48